journal article·2009-09-02

Structural and Physicochemical Characterization of a Solid Solution Produced by Antisolvent Crystallization of a New Phosphoantigen

Guillaume Descamps, Yohann Cartigny, Morgane Sanselme, Marie-Noëlle Petit, Samuel Petit, Eric Aubin, Gérard Coquerel

Crystal Growth & Design· Volume 9· Issue 9
Publisher page

Abstract

During the crystallization of the monohydrated disodium salt of hydroxydimethylallyl pyrophosphonate (C-HDMAPP·Na 2 ·H 2 O) induced by addition of ethanol to an aqueous solution, a synthesis impurity (C-ethylPP 2− ) can be incorporated into the crystal lattice. Owing to the chemical similarity between the two anionic molecular entities, a solid solution of substitution type is produced and has been characterized by X-ray powder diffraction (XRPD), thermal analysis, and dynamic vapor sorption (DVS). Besides the incidence of the solid solution on diffraction peak positions caused by expansion/contraction of the lattice, XRPD revealed that a distinct crystalline phase is obtained when the proportion of impurity is higher than ca. 20 wt %. The crystal structure of both C-HDMAPP·Na 2 ·H 2 O and C-ethylPP·Na 2 phases were determined, which allowed molecular modeling investigations. A mechanism has been proposed to explain the substitution at a molecular level and is consistent with the correlation observed between the actual water content (nonstoichiometry) and the proportion of impurity in the solid solution of global formula C-HDMAPP 1− x ·C-ethylPP x ·Na 2 ·(H 2 O) 1+2 x, (0 ≤ x ≤ 0.26).
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Chemical Synthesis and Characterization · Crystallography and molecular interactions · Organophosphorus compounds synthesis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Unité de Croissance Cristalline et de Modélisation Moléculaire, SMS UPRES EA 3233-IRCOF, Université de Rouen, F-76821 Mont Saint Aignan Cedex, France

Innate Pharma, 117 avenue de Luminy, F-13009 Marseille, France

References (23)

Show source-provided references
1. Coquerel G. · Chem. Eng. Proc. · 2006 · 45 · 85710.1016/j.cep.2005.10.011 ↗
2. Fiebig A. · Cryst. Growth Des. · 2007 · 7 · 162310.1021/cg070073v ↗
3. Ottens M. · Ind. Eng. Chem. Res. · 2004 · 43 · 793210.1021/ie0307028 ↗
4. Rodriguez-Hornedo N. · J. Pharm. Sci. · 1999 · 88 · 65110.1021/js980490h ↗
5. Morris K. R. · Adv. Drug Delivery Rev. · 2001 · 48 · 9110.1016/S0169-409X(01)00100-4 ↗
6. Garnier S. · Int. J. Pharm. · 2008 · 361 · 13110.1016/j.ijpharm.2008.05.023 ↗
7. Espinosa E. · J. Biol. Chem. · 2001 · 276 · 1833710.1074/jbc.M100495200 ↗
8. Espinosa E. · Microbes Infection · 2001 · 3 · 64510.1016/S1286-4579(01)01420-4 ↗
9. Boedec A. · J. Med. Chem. · 2008 · 51 · 174710.1021/jm701101g ↗
10. Kirkova E. · Progr. Cryst. Growth Charact. Mater. · 1996 · 32 · 11110.1016/0960-8974(96)00007-1 ↗
11. 2001
12. 1999
13. 2000
14. Renou L. · Cryst. Growth. Des · 2007 · 7 · 159910.1021/cg070075f ↗
15. Huang J. · J. Am. Chem. Soc. · 2006 · 128 · 1198510.1021/ja063450l ↗
16. Wermester N. · Tetrahedron: Asymmetry · 2007 · 18 · 82110.1016/j.tetasy.2007.03.011 ↗
17. Lin S. W. · Comput. Chem. Eng. · 2008 · 32 · 95610.1016/j.compchemeng.2007.04.005 ↗
18. Duddu S. P. · Int. J. Pharm. · 1996 · 127 · 5310.1016/0378-5173(95)04117-6 ↗
19. Zhang G. G. Z. · Int. J. Pharm. · 1999 · 181 · 6110.1016/S0378-5173(98)00419-0 ↗
20. Grandeury A. · J. Phys. Chem. B · 2007 · 111 · 701710.1021/jp071428o ↗
21. Authelin J.-R. · Int. J. Pharm. · 2005 · 303 · 3710.1016/j.ijpharm.2005.07.007 ↗
22. Schmidt A. C. · Int. J. Pharm. · 2006 · 320 · 410.1016/j.ijpharm.2006.04.017 ↗
23. Van Der Sluis P. · J. Cryst. Growth · 1989 · 97 · 64510.1016/0022-0248(89)90566-6 ↗